Evidence map›Paper›PMID 31602272›Full record

ArticleJournal of Cancer2019

AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma.

Zhenfeng Zhao, Shuguang Zhou, Wenyu Li, Fei Zhong, Heping Zhang, Lei Sheng, Yue Li, Meng Xu, Jifei Xu, Lei Zhan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Zhenfeng ZhaoDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shuguang ZhouDepartment of Gynecology, Maternity and Child Healthcare Hospital of Anhui Medical University, Hefei, China.
Wenyu LiDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Fei ZhongDepartment of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China.
Heping ZhangDepartment of Pathology, Maternity and Child Healthcare Hospital of Anhui Medical University, Hefei, China.
Lei ShengDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yue LiDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Meng XuDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jifei XuDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Lei ZhanPathology Department of Anhui Medical University, Hefei, China.
Bao LiThe Comprehensive Lab, College of Basic medicine, Anhui Medical University, Hefei, China.
Fan WangDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Dan XieState Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhuting TongDepartment of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amplified in breast cancer 1 (AIB1) gene, has been reported to be associated with biological malignancy in several cancers. However, the molecular status of the AIB1 gene in cervical cancer and the clinicopathological/prognostic significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity have not been determined. In our present study, we found that the high expression of AIB1 was frequent detected in specimens of cervical cancer patients, and this was significantly correlated with CRT response (

Indexed as

AIB1Cervical cancerchemoradiotherapyimmunohistochemistryLinear-Quadratic Model

Identifiers

PMID31602272
PMCPMC6775615
OpenAlexW2972789547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.